The Biostatistics Shared Resource (BSR) of the Mayo Clinic Cancer Center (MCCC), under the leadership of Dr. Daniel Sargent, PhD (since 2001) has provided expert statistical collaboration with MCCC investigators for over 40 years for the development and conduct of peer-reviewed cancer center research encompassing basic science, clinical trials, epidemiologic research, and other translational and educational research. The primary usage of CCSG funds within the BSR is to support statistical collaboration on pilot projects, for assistance to investigators in developing approved research projects not otherwise funded but leading towards external funding, and to support unanticipated needs for statistical collaboration on MCCC approved projects. Funding is primarly provided to protect FTE of key faculty members to collaborate with MCCC members at no charge;funding is also provided to select senior MS statisticans for work on approved MCCC projects. In the current grant period the BSR has successfully and strategically firmly established high dimensional genomic and proteomic data analysis, and a robust presence at all 3 MCCC campuses. BSR faculty includes statistical methodological research leaders in clinical trial design, survival analysis, high-dimensional data, statistical genetics, quality of life research, and surrogate endpoints. The BSR has three focus areas (teams) tied together into a well-organized, efficient core. These are: (I) a Clinical Trials team responsible for cancer clinical trials, associated translational research, and patient and public education research projects, (11) a Population Science/Computational Genomics team responsible for statistical collaboration and data management support for high dimensional data analyses and cancer observational studies, including genetic and molecular epidemiology, and (III) a Quality of Life team responsible for collaboration, measurement tools, and analysis for MCCC investigators investigating the impact of clinical and psychosocial interventions on cancer patients, families, caregivers, and others. The BSR has been remarkably productive, with authorship on 833 peer reviewed publications and collaborations on 63 NIH or NIH-equivalent grants in the current grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682938
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$576,349
Indirect Cost
$214,152
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434

Showing the most recent 10 out of 1129 publications